Achieve Life Sciences shares jump 10.36% intraday as Hunterbrook Capital discloses long position ahead of FDA decision.

Achieve Life Sciences surged 10.36% intraday after Hunterbrook Capital disclosed a long position in the company, signaling confidence ahead of an upcoming FDA decision on cytisinicline, a smoking cessation therapy. The FDA is set to rule on June 20, with a potential U.S. launch by late 2026 if approved. The drug, supported by successful Phase 3 trials and Breakthrough Therapy Designation, already available in Europe, is positioned as a safer alternative to withdrawn U.S. treatments like Chantix. Hunterbrook’s thesis highlighted the drug’s market potential and the company’s $48 million in cash reserves, sufficient for nine months of operations. The firm also secured a $5 million convertible loan, easing near-term liquidity concerns. The bullish move reflects investor optimism over regulatory progress and commercialization prospects.